EPISODE · Jan 5, 2024 · 37 MIN
Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024
from BioCentury This Week · host BioCentury
A flurry of large acquisitions to close out 2023 is likely to carry into the New Year as pharmas continue to show appetite for late-stage assets. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the latest trends in biotech M&A, potential takeout targets for 2024 and the impact on dealmaking of a more aggressive FTC. They also assess sentiment heading into next week’s J.P. Morgan Healthcare Conference, analyze future drivers of innovation in biotech, and preview the year ahead in regulation and public policy.Music for the 24th Bio€quity Europe teaser produced by:Thomas de Paula Eby, Andreas Unge, Epidemic Sound via Getty ImagesReach us by sending a text
Embed this episode
What this episode covers
A flurry of large acquisitions to close out 2023 is likely to carry into the New Year as pharmas continue to show appetite for late-stage assets. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the latest trends in biotech M&A, potential takeout targets for 2024 and the impact on dealmaking of a more aggressive FTC. They also assess sentiment heading into next week’s J.P. Morgan Healthcare Conference, analyze future drivers of innovation in biotech, and preview th...
NOW PLAYING
Ep. 209 - Biotech M&A, Innovation, Public Policy in 2024
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.